Kornimate/medical-research-clean huggingface dataset:
regulation of postprandial nitric oxide bioavailability and vascular function by dairy fat

Conditions: Prediabetes

Summary: cardiovascular disease (cvd) is the leading cause of death in the united states. short-term increases in blood sugar, or postprandial hyperglycemia (pph), affect blood vessel function and increase the risk of cvd. greater intakes of dairy foods have been associated with a lower risk of cvd, but whether these effects occur directly or indirectly by displacing foods in the diet that might increase cvd risk is unclear. further controversial is the extent to which dietary fat derived from dairy foods regulate the risk of cvd. the health benefits of dairy on cvd risk are at least partly attributed to its ability to limit pph and resulting pph-mediated responses leading to vascular dysfunction. this provides rationale to investigate full-fat containing dairy as a dietary strategy to reduce pph and risk for heart disease. the objective of this project is to define the extent to which full-fat dairy milk compared to non-fat dairy milk protects against pph-induced vascular dysfunction by reducing oxidative stress responses that limit nitric oxide bioavailability to the vascular endothelium in adults with prediabetes.

this study consists of three, 3-hour postprandial trials in response to consuming the following dietary treatments: 1. oral glucose challenge, 2. oral glucose challenge in combination with non-fat milk, and 3. oral glucose challenge in combination with whole milk. for three days preceding each trial, participants will be provided all meals to standardize physiologic responses to test meals. on each trial day, vascular function will be assessed and blood samples collected prior to and at 30 minute intervals for 3 hours following test meal ingestion.

Eligibility criteria:
inclusion criteria: 1. hemoglobin a1c 5.7-6.4% 2. non-dietary supplement user 3. no medications affecting vasodilation, inflammation, or energy metabolism 4. no cvd 5. nonsmokers 6. individuals having blood pressure \<140/90 mmhg and total cholesterol \<240 mg/dl exclusion criteria: 1. unstable weight (±2 kg) 2. vegetarian or dairy allergy 3. alcohol intake \>3 drinks/day or \>10 drinks/week 4. ≥ 7 hours/week of aerobic activity

Keywords: dairy milk glucose postprandial hyperglycemia prediabetes blood glucose oxidative stress vascular health vascular function
monosialoganglioside preventing neurotoxicity induced by albumin-bound paclitaxel chemotherapy in lung cancer patients

Conditions: Neurotoxicity

Summary: the purpose of this study is to determine whether monosialoganglioside are effective in the prevention of neurotoxicity induced by albumin-bound paclitaxel chemotherapy in lung cancer patients, and improve the quality of life of patients.

lung cancer patients received a single-agent albumin-bound paclitaxel chemotherapy are included in this trial. patients are randomly assigned into the experimental group and blank control group based on segmented block randomized method. after enrollment, patients will complete at least chemotherapy and gm1 injection/blank control. during the 3w per cycle chemotherapy, albumin-bound paclitaxel is conducted in d1 and d8, gm1(40mg+250ml n.s) is injected from d1 to d8. neurotoxicity evaluation and quality of life assessment will be conducted every cycle and 3m/6m after the chemotherapy.

Eligibility criteria:
inclusion criteria: * cytological and histological confirmation of unresectable locally advanced or metastatic lung cancer diagnosis * no peripheral nervous system diseases exists before * within 4 weeks before treatment, did not receive other adverse reaction of drugs may cause similar neurotoxicity * enough organ functions reservation and appropriate performance status for chemotherapy * expected survival period is more than 3 months exclusion criteria: * known or assignment of any of these products to test drugs allergic agent composition * with peripheral neuropathy by any cause before treatment * with other neurological dysfunction which can cause inaccurate record of the occurrence of neurotoxicity and severity * patients with poor general condition to receive chemotherapy * genetic glucolipid metabolic abnormalities * patients (male or female) have fertility possibility but not willing to or not to adopt effective contraception * patients cann't avoid neurotrophic drugs * according to the researcher's judgment, the situations inappropriate for patients with ganglioside medication

Keywords: neurotoxicity chemotherapy monosialoganglioside prevention
comparison of skin adhesive to subcuticular suture wound closure after port placement

Conditions: Wound Closure After Port Catheter Implantation

Summary: port wound closure compares synthetic tissue adhesives with seam for cutaneous wound closure to port plant in terms of cosmetic results and time savings at comparable risk for wound infection.

study patients who undergo a subcutaneous venous port implant procedure are randomized into control group (conventional sutures) or into interventional group (synthetic tissue adhesive). the intervention time is documented. follow-up visit is performed 8 weeks after port implantation. it includes a photo documentation, quality of life questionnaire (eq5d) and pain scala questionnaire (posas) by patient and by 3 independent observers as well as the documentation of complications.

Eligibility criteria:
inclusion criteria: * medical indication for port catheter implantation because of chemotherapy or parenteral nutrition exclusion criteria: * children and adolescents \< 18 years * thrombocytes \< 50/nl * ptt \<50% * inr \>1.5 * systemic or local infection of the interventional location * known allergy to used material * known allergy to histoacryl, cyanoacrylate, d\&c violett or formaldehyd * general contraindication of port catheter implantation

Keywords: skin adhesive suture port incisions
perception about benefits and risks related to combined hormonal contraceptives use in patients with lynch syndrome

Conditions: Lynch Syndrome; Contraception

Summary: combined hormonal contraceptives (chcs), according to the opinion by the manchester international consensus group, should be considered for women wishing contraception because also positively impact endometrial cancer and ovarian cancer risk. the awareness of the effects of hormonal therapies in women at high risk of developing endometrial cancer, colorectal, breast, or ovarian cancer, such as those affected by lynch syndrome (ls), is currently limited, with few published studies addressing these populations. making informed decisions about chc use in this context necessitates careful consideration of individual cancer risk and the potential benefits and risks associated with chc use. accurate information regarding the oncological risks associated with chc use is essential for facilitating shared decision-making between women and their healthcare providers in this patient population. this prospective study aims to evaluate the knowledge, attitudes, and beliefs of women with ls concerning chcs and their potential effects on specific disease development and cancer risk, comparing them to the general population. by considering psychosocial factors and individual perceptions of cancer risk, this study seeks to contribute to informed decision-making, personalized counseling, and improved strategies for gynecologic cancer risk management in women with ls.


Eligibility criteria:
inclusion criteria: * patients with certain genetic diagnosis of lynch syndrome and patients of reproductive age undergoing routinely gynecological visit exclusion criteria: * for both groups, a prior history of oncological diseases and a personal history of endometrial cancer, colorectal cancer, ovarian cancer, or breast cancer. * for patients with lynch syndrome, individuals who had undergone previous risk-reducing prophylactic surgical approaches such as (risk-reducing) colectomy, hysterectomy, early salpingectomy, and delayed oophorectomy, and risk-reducing salpingo-oophorectomy

Keywords: lynch syndrome
evaluating the effect of anakinra (r-methuil-1ra) on vaccine antibodyresponse in subjects with rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to estimate the effect of anakinra, 100 mg once daily (qd), on the development of an anti-tetanus antibody response in subjects with ra after vaccination with a tetanus and diphtheria toxoids injection. in addition, this study will evaluate the general safety profile of therapy with anakinra, 100 mg qd, in subjects with ra after vaccination with a tetanus and diphtheria toxoids injection.


Eligibility criteria:
inclusion criteria: - diagnosed with ra by american college of rheumatology (acr) criteria for greater than or equal to 12 weeks - active ra with at least 3 swollen joints and 3 tender/painful joints and at least one of the following: * morning stiffness greater than or equal to 45 minutes; * c-reactive protein (crp) greater than or equal to 1.5 mg/dl; * erythrocyte sedimentation rate greater than or equal to 28 mm/hr; * stable methotrexate dose of less than or equal to 20 mg/week for 8 weeks prior to randomization; * stable doses of nonsteroidal anti-inflammatory drugs (nsaids) and oral corticosteroids (less than or equal to 10 mg/day of prednisone or equivalent) for 4 weeks prior to randomization. exclusion criteria: - pregnant or breast-feeding women - any uncontrolled, clinically significant systemic disease - has total white cell count less than 3.5 x 10\^9/l, a neutrophils count less than 2.0 x 10\^9/l, platelet count less than 125 x 10\^9/l or hemoglobin (hgb) less than 8.0 g/dl at screening - abnormal liver function tests (ast/alt greater than or equal to 1.5 x the upper limit of normal at screening) - serum creatinine greater than 1.5 x the upper limit of normal at screening - subject recall of having tetanus toxoid or diphtheria vaccination less than 10 years prior to randomization - has never received a primary tetanus vaccination - any other vaccination within 12 weeks of randomization - disease-modifying antirheumatic drugs (dmards) other than methotrexate - biologics to treat ra within the previous 8 weeks of screening (e.g., etanercept, infliximab) - subjects were treated with anakinra within 4 weeks prior to randomization

Keywords: rheumatoid arthritis, inflammation interleukin-1 (il-1), r-methuil-1ra autoimmune, kineret® anakinra, immunex amgen, clinical trials
high-shear microfluidic thrombosis assay

Conditions: Coagulation Defects, Other and Unspecified

Summary: the purpose of this study is to characterize a new test to assess the rate and time it takes to form a blood clot in people who either do or do not take aspirin.

it is estimated that approximately 25% of people are resistant to aspirin, or do not respond to its effect. these individuals have a four fold higher risk of a heart attack or stroke compared to those who respond to aspirin. current tests for determining those who are aspirin resistant are not reliable. this study is assessing the effectiveness of a new assay in determining the rate and time it takes for people who are or are not on aspirin in forming a blood clot.

Eligibility criteria:
inclusion criteria for "no aspirin" group: * have not taken aspirin, other nonsteroidal anti-inflammatory drugs (nsaids), or clopidogrel in the previous 10 days * no history of myocardial infarction, ischemic stroke, or other ischemic event inclusion criteria for "aspirin daily" group: * have taken aspirin daily over the last 10 days or more * no history of myocardial infarction, ischemic stroke, or other ischemic event inclusion criteria for "new to aspirin" group: * have not previously been prescribed aspirin, but have been prescribed aspirin at their present appointment, e.g. a high calcium plaque score on ct * no history of myocardial infarction, ischemic stroke, or other ischemic event exclusion criteria: * a known bleeding or thrombotic disorder exclusion criteria for "new to aspirin" group: * a known bleeding or thrombotic disorder * have taken aspirin, other nsaids, clopidogrel, or an anticoagulant in the previous 10 days
intraoperative ansa cervicalis nerve (acn) stimulation

Conditions: Head and Neck Cancer; Obstructive Sleep Apnea

Summary: recently published data suggest that stimulation of the infrahyoid strap muscles increases pharyngeal patency in patients with obstructive sleep apnea, but the innervation of these muscles by the ansa cervicalis is variable. the investigators propose a study examining the anatomic variation of the ansa cervicalis and the effect of neurostimulation on muscle recruitment.

this is a single-arm physiology study. consenting patients undergoing neck dissection (nd) for cervical lymphadenectomy of level iv will undergo dissection of the ansa cervicalis nerves to the infrahyoid strap muscles. per routine care, a large incision is made across the neck to provide surgeons access to the cervical lymph nodes for extirpation. during this dissection, the branch(es) of the ansa cervicalis nerve plexus descending from the loop of the plexus and innervating the infrahyoid strap muscles (the "common trunk") are dissected uni- or bilaterally. for this study, measurements and photos/videos of the common trunks will be taken. an electrode will be placed on one or both common trunks to stimulate infrahyoid muscles.

Eligibility criteria:
inclusion criteria: * adult patient (≥18 years old). * scheduled for uni- or bilateral neck dissection (bnd) for cervical lymphadenectomy of level iv and other indicated procedures for management of head and neck cancer. exclusion criteria: * unable to consent for research due to a pre-existing neurologic condition as determined by pi. * unable to consent for research due to language barriers. * history of prior neck surgery with transection of the infrahyoid strap muscles as determined by clinical history.
laparoscopic cholecystectomy: general anesthesia with opioid versus general opioid free anesthesia

Conditions: Pain, Postoperative; Anesthesia Complication; Nausea; Vomiting; Ileus Paralytic; Hemodynamic Instability

Summary: the use of opioid during surgery can cause side effects and may delay hospital discharge. some studies have shown balanced sparing opioid anesthesia can optimize the side effects and and the time of discharge. in this compared controlled randomized study the aim is to evaluate the intraoperative and postoperative pain, hemodynamic effects, nausea/vomiting, postoperative ileus, sedation, urinary retention, time of discharge pacu post anesthesia care unit and hospital.

patients under laparoscopic cholecystectomy has moderate to severe pain. this study will compare intraoperative hemodynamic parameters under two techniques of general anesthesia: the primary outcome pain was used for planning the sample size of participants and considered a variation of 3 points on vas (visual analogic scale of pain). the secondaries outcomes nausea/vomiting, sedation, ileus paralytics, urinary retention, time of discharge (pacu) and hospital stay, and patient satisfaction will be recorded and analyzed. the patients will be allocated from randomized program in one of the two arms. 1. based opioid balanced anesthesia propofol, fentanyl, rocuronium and isoflurane 2. opioid sparing balance anesthesia with propofol, dexter- ketamine, clonidine, midazolan,isoflurane and lidocaine. at the end of procedure both groups will receive dexamethasone, ranitidine , ondansetron, keterolac iv and local infiltration of bupivacaine on trocar wounds as multimodal analgesia. general anesthesia opioid free seems to have less side effects than the general anesthesia based on opioid this study will compare it.

Eligibility criteria:
inclusion criteria: * patient under laparoscopic cholecystectomy routine american society of anesthesiology asa i or ii exclusion criteria: * chronic use of opioids * body mass index (bmi) \> 35 kg.m-2 * chronic heart failure, renal and hepatic failure * illicit drugs users * cognitive impairments
effect of early enteral tube feeding nutrition with an immune enhancing diet in severe burn patients

Conditions: Infections on; Severe Burn Patients

Summary: compare clinical and biological effects of two enteral tube feeding nutrition formula (immune enhancing diet versus polymeric diet)in severe burn hospitalized patients .


Eligibility criteria:
inclusion criteria: * thermic burn from 20% to 80% * 15 \< age \< 70 years * written informed consent exclusion criteria: * diabetes mellitus * corticoid or immuno-suppressive therapy * hiv * evolutive cancers * pregnancy * abdominal lesion * hepatic or renal failure

Keywords: infections
suprascapular notch cross-sectional area measured by ultrasonography

Conditions: Shoulder Pain; Shoulder Impingement Syndrome

Summary: chronic shoulder pain is one of the most common diseases affecting the quality of life today. although there are multiple causes, one of the most common causes is shoulder impingement syndrome. ultrasound can be used for diagnosis in patients whose treatment is difficult due to its complex structure. while the supraspinatus muscle, tendon and shoulder joint are the regions that are usually evaluated, the visualization of the suprascapular notch is usually observed during injection. the connection between the suprascapular notch and the shoulder joint has been demonstrated in different studies.

in this study, the investigation of the relationship between the measurements of the suprascapular nerve and the suprascapular notch, which the investigators observed in our clinical ultrasound applications, and the disease activity intended.

Eligibility criteria:
inclusion criteria: * chronic shoulder pain * 35-65 years * who agreed to participate in the study exclusion criteria: * . lymphoproliferative diseases and other neoplasms * .uncontrolled arterial hypertension * metabolic syndrome * uncontrolled diabetes mellitus * mental retardation * antidepressant use * autoimmune diseases
mechanisms of macrophage polarization in hiri in patients with nafld

Conditions: Hepatic Ischemia-reperfusion Injury; Non-alcoholic Fatty Liver Disease

Summary: to better understand the occurrence of hepatic ischemia-reperfusion injury (iri) in patients with non-alcoholic fatty liver disease (nafld) and the role of macrophage polarization in this process, this study will retrospectively collect clinical data from patients who underwent partial hepatectomy at beijing tsinghua changgung hospital between september 2021 and march 2025. additionally, clinical information and liver blood samples from patients scheduled for partial hepatectomy from april 2025 onward will be prospectively collected. these samples will include normal liver tissue from the resected portion, as well as 5 ml of venous blood obtained before and after surgery. the investigators will compare the severity of hepatic iri, the expression of macrophage polarization-related proteins, and macrophage polarization markers in blood samples between nafld patients and controls. the study aims to determine whether nafld patients experience more severe hepatic iri and to elucidate the role and mechanisms of macrophage polarization in this context. the findings will provide a theoretical basis for understanding the molecular mechanisms underlying hepatic iri in nafld patients, thereby identifying potential therapeutic targets to prevent iri and improve prognosis in nafld patients undergoing partial hepatectomy.


Eligibility criteria:
inclusion criteria: * the vital organ systems (heart, lungs and kidneys) have sufficient functional reserves. exclusion criteria: * no hepatic inflow occlusion (pringle maneuver) was applied during surgery. * american society of anesthesiologists (asa) physical status classification \> grade iii. * secondary causes of hepatic steatosis were excluded, including viral hepatitis, drug-induced liver injury, total parenteral nutrition, wilson's disease, and autoimmune liver diseases. * prior chemotherapy or radiotherapy before the planned surgery. * use of anticoagulant medications.
accuracy testing of the chromosomal aberration and gene mutation markers of the amlprofiler

Conditions: Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Refractory Anemia With Excess of Blasts (RAEB)

Summary: this clinical study will demonstrate the accuracy of the chromosomal aberration and gene mutation markers of the amlprofiler molecular diagnostic assay and generate clinical performance data to support a pre-market approval (pma) submission to the food and drug administration for in vitro diagnostic use within the united states of america. the objective is to demonstrate the positive and negative percent agreement of each marker by comparing amlprofiler results from multiple clinical participating sites with data generated using a laboratory developed bi-directional sequencing method generated at the molecular diagnostic reference lab. the amlprofiler assay is a qualitative in vitro diagnostic test for the detection of aml or apl specific chromosomal aberrations (specific recurrent translocations and inversions), as well as expression of specific genetic markers in rna extracted from bone marrow aspirates of patients with acute myeloid leukemia.


Eligibility criteria:
inclusion criteria: 1. subjects with a cytopathologically confirmed diagnosis of aml subjects with refractory anemia with excess of blasts (raeb) according to the who 2008 classification 2. ≥ 18 years 3. written informed consent exclusion criteria: 1. subjects without a cytopathologically confirmed diagnosis of aml subjects with refractory anemia with excess of blasts (raeb) according to the who 2008 classification 2. \< 18 years 3. without written informed consent
feasibility of identifying, enrolling and following acute and early hiv-1 infected individuals.

Conditions: Acute Human Immunodeficiency Virus Type I Infection

Summary: it is only between peak viremia and viral setpoint in natural acute hiv-1 infection that the immune response overwhelms viral replication resulting in a plasma viral load decline. the aim will be to characterize these immune responses, how they develop and their progeny. this will require the need to identify hiv-1 infected individuals before peak viremia and follow them to post viral setpoint. this protocol describes a pilot study to evaluate the feasibility of identifying, enrolling and following acute and early hiv-1 infected individuals from voluntary counselling and testing centres in masaka, bukomansimbi, kalungu, lwengo, sembababule and lyantonde districts.


Eligibility criteria:
inclusion criteria: * females and males. * able and willing to provide informed consent. * willing to undergo hiv testing using genex pert viral load assay. * able and willing to provide accurate locator information for tracking purposes and willing to be contacted by study staff. * willing to complete interviewer administered questionnaires on risk factors and if infected, questions related to the route and timing of exposure. exclusion criteria: has any condition that in the opinion of the principal investigator or designee, would preclude provision of informed consent, or otherwise interfere with achieving the study objectives. * participation in a current clinical trial unless approved by the investigators and iavi medical monitor.

Keywords: hiv-1, immune responses, cell death, acute